Clinical trials for recurrent GBM using a bifunctional antibody targeting EGFR and coupled to a microtubule-disrupting agent have been completed, and a study adding this agent to the standard chemoradiation and adjuvant temozolomide is ongoing (NCT02573324). The gene discussed is EGFR; the disease is glioblastoma.